Get the Stockscreener App
1.36
1.45%
-0.02
After Hours:
1.36
Lexicon Pharmaceuticals Inc stock is traded at $1.36, with a volume of 1.90M.
It is down -1.45% in the last 24 hours and down -3.55% over the past month.
Lexicon Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in the discovery, development, and commercialization of pharmaceutical products for the treatment of human diseases. Some of its drug candidates are LX9211, an orally-delivered small molecule drug candidate, also developing LX9851, an orally-delivered small molecule drug candidate, as a treatment for obesity and associated cardiometabolic.
See More
Previous Close:
$1.38
Open:
$1.38
24h Volume:
1.90M
Relative Volume:
0.82
Market Cap:
$494.22M
Revenue:
$1.21M
Net Income/Loss:
$-177.12M
P/E Ratio:
-1.70
EPS:
-0.8
Net Cash Flow:
$-162.37M
1W Performance:
-2.16%
1M Performance:
-3.55%
6M Performance:
+99.82%
1Y Performance:
+11.48%
1-Day Range:
$1.35
$1.39
1-Week Range:
$1.3031
$1.41
52-Week Range:
$0.2836
$1.66
Lexicon Pharmaceuticals Inc Stock (LXRX) Company Profile
Name
Lexicon Pharmaceuticals Inc
Sector
Industry
Phone
(281) 863-3000
Address
2445 TECHNOLOGY FOREST BLVD., THE WOODLANDS
Compare LXRX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LXRX
Lexicon Pharmaceuticals Inc
|
1.36 | 501.49M | 1.21M | -177.12M | -162.37M | -0.80 |
|
VRTX
Vertex Pharmaceuticals Inc
|
426.00 | 109.11B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
642.25 | 68.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
434.07 | 60.25B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
826.28 | 50.39B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
186.23 | 40.44B | 447.02M | -1.18B | -868.57M | -6.1812 |
Lexicon Pharmaceuticals Inc Stock (LXRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-05-25 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Jun-17-24 | Initiated | H.C. Wainwright | Buy |
| Apr-30-24 | Initiated | Leerink Partners | Outperform |
| Mar-07-23 | Initiated | Jefferies | Hold |
| Aug-12-22 | Initiated | Piper Sandler | Overweight |
| Jan-29-21 | Upgrade | JP Morgan | Underweight → Neutral |
| Jan-29-21 | Downgrade | Wedbush | Outperform → Neutral |
| Dec-08-20 | Upgrade | Citigroup | Neutral → Buy |
| Nov-18-20 | Upgrade | Gabelli & Co | Hold → Buy |
| Dec-11-19 | Downgrade | Gabelli & Co | Buy → Hold |
| Nov-08-19 | Downgrade | Citigroup | Buy → Neutral |
| Sep-11-19 | Upgrade | Gabelli & Co | Hold → Buy |
| Jul-29-19 | Downgrade | Stifel | Buy → Hold |
| Mar-25-19 | Upgrade | Gabelli & Co | Sell → Hold |
| Jul-31-18 | Reiterated | Stifel | Buy |
| Feb-23-18 | Downgrade | Needham | Buy → Hold |
| Feb-14-18 | Downgrade | JP Morgan | Neutral → Underweight |
| Mar-01-17 | Reiterated | H.C. Wainwright | Buy |
| Mar-01-17 | Reiterated | Wedbush | Outperform |
| Oct-07-16 | Initiated | H.C. Wainwright | Buy |
| Aug-05-16 | Reiterated | Wedbush | Outperform |
| Aug-02-16 | Initiated | Citigroup | Buy |
| Mar-02-16 | Reiterated | Wedbush | Outperform |
| Nov-09-15 | Reiterated | Wedbush | Outperform |
| Sep-28-15 | Upgrade | Gabelli & Co | Sell → Hold |
| Sep-18-15 | Downgrade | Gabelli & Co | Hold → Sell |
| Aug-10-15 | Downgrade | JP Morgan | Overweight → Neutral |
View All
Lexicon Pharmaceuticals Inc Stock (LXRX) Latest News
What MACD signals say about Lexicon Pharmaceuticals Inc.Earnings Overview Summary & Fast Momentum Stock Entry Tips - newser.com
What the charts say about Lexicon Pharmaceuticals Inc. today2025 Price Action Summary & Weekly Market Pulse Alerts - newser.com
Applying Wyckoff theory to Lexicon Pharmaceuticals Inc. stockGlobal Markets & Free Reliable Trade Execution Plans - newser.com
Why Lexicon Pharmaceuticals Inc. stock remains a top recommendation2025 Top Gainers & Daily Chart Pattern Signal Reports - newser.com
Is Lexicon Pharmaceuticals Inc. stock attractive for growth ETFsJuly 2025 Setups & Accurate Trade Setup Notifications - newser.com
Using data tools to time your Lexicon Pharmaceuticals Inc. exitQuarterly Market Review & Real-Time Sentiment Analysis - newser.com
Is Lexicon Pharmaceuticals Inc. stock attractive for hedge fundsQuarterly Growth Report & Verified Trade Idea Suggestions - newser.com
What candlestick patterns are forming on Lexicon Pharmaceuticals Inc.2025 Pullback Review & Fast Entry High Yield Stock Tips - newser.com
Published on: 2025-10-31 04:02:24 - newser.com
Lexicon Pharmaceuticals, Inc. (LXRX) Analyst insights, Price targets and Recommendations - Yahoo! Finance UK
Lexicon Pharmaceuticals to Report Third Quarter 2025 Financial Results on November 6, 2025 - The Manila Times
Lexicon (NASDAQ: LXRX) sets Nov. 6 call for third quarter results at 8:30 a.m. ET - Stock Titan
Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Q4 2024 Earnings Call Transcript - MSN
How analysts rate Lexicon Pharmaceuticals Inc. stock todayLayoff News & Free Real-Time Volume Trigger Notifications - Fundação Cultural do Pará
Is Lexicon Pharmaceuticals Inc. stock a defensive play in 2025Weekly Earnings Recap & Free Accurate Trade Setup Notifications - fcp.pa.gov.br
Weiss Ratings Reaffirms "Sell (D-)" Rating for Lexicon Pharmaceuticals (NASDAQ:LXRX) - MarketBeat
Lexicon Pharmaceuticals Inc Stock (LXRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.64%
0.35%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):